Molecular mechanisms of sunitinib resistance in renal cell carcinoma

Simon, Turibius, Gobe, Glenda C., Wu, Chung-Shu, Ko, Fu-Hsiang and Morais, Christudas (2014). Molecular mechanisms of sunitinib resistance in renal cell carcinoma. In Christudas Morais (Ed.), Advances in Drug Resistance Research (pp. 225-246) New York, United States: Nova Biomedical.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
Author Simon, Turibius
Gobe, Glenda C.
Wu, Chung-Shu
Ko, Fu-Hsiang
Morais, Christudas
Title of chapter Molecular mechanisms of sunitinib resistance in renal cell carcinoma
Title of book Advances in Drug Resistance Research
Place of Publication New York, United States
Publisher Nova Biomedical
Publication Year 2014
Sub-type Critical review of research, literature review, critical commentary
Open Access Status
Series Public Health in the 21st Century
ISBN 9781631171314
9781631171383
Editor Christudas Morais
Chapter number 9
Start page 225
End page 246
Total pages 22
Total chapters 9
Collection year 2015
Language eng
Formatted Abstract/Summary
Renal cell carcinoma (RCC) is a treatment resistant cancer. The identification of the link between the von Hippel Lindau (VHL) gene and the vascular endothelial growth factor (VEGF) pathway has led to development of the multi-tyrosine kinase inhibitor sunitinib. The introduction of sunitinib in clinical practice for the treatment of metastatic RCC has significantly increased the overall survival of patients. However resistance to sunitinib is emerging as a challenge. About 30% of patients are intrinsically resistant to sunitinib and almost all patients who show initial response to sunitinib develop extrinsic (acquired) resistance after a median of 6–15 months. While the molecular mechanisms of sunitinib resistance are multifactorial, the emerging consensus is that, sustained VEGF/VEGF receptor (VEGFR) inhibition by sunitinib ‗resets‘ the tumor microenvironment leading to the development of VEGF/VEGFRindependent alternate angiogenic pathways. This chapter summarises the advances in understanding of the molecular mechanisms of sunitinib resistance in RCC.
Keyword Renal cell carcinoma
Sunitinib
Q-Index Code B1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Book Chapter
Collections: Non HERDC
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Sun, 02 Mar 2014, 14:34:02 EST by Dr Christudas Morais on behalf of Medicine - Princess Alexandra Hospital